Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Personalized estimates of breast cancer risk in clinical practice and public health.

Gail MH.

Stat Med. 2011 May 10;30(10):1090-104. doi: 10.1002/sim.4187. Epub 2011 Feb 21.

2.

Assessing women at high risk of breast cancer: a review of risk assessment models.

Amir E, Freedman OC, Seruga B, Evans DG.

J Natl Cancer Inst. 2010 May 19;102(10):680-91. doi: 10.1093/jnci/djq088. Epub 2010 Apr 28. Review.

PMID:
20427433
3.

Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk.

Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, Vogel V, Shepherd J, Vachon C, Smith-Bindman R, Kerlikowske K.

J Natl Cancer Inst. 2009 Mar 18;101(6):384-98. doi: 10.1093/jnci/djp018. Epub 2009 Mar 10. Review.

4.

Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V.

J Natl Cancer Inst. 1999 Nov 3;91(21):1829-46. Review. Erratum in: J Natl Cancer Inst 2000 Feb 2;92(3):275.

PMID:
10547390
5.

Chemoprevention of breast cancer. A joint guideline from the Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

Levine M, Moutquin JM, Walton R, Feightner J; Canadian Task Force on Preventive Health Care and the Canadian Breast Cancer Initiative's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer.

CMAJ. 2001 Jun 12;164(12):1681-90. Review.

6.

Breast cancer risk reduction: what do we know and where should we go?

Prout MN.

Medscape Womens Health. 2000 Sep-Oct;5(5):E4. Review.

PMID:
11113777
7.

American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

Chlebowski RT, Collyar DE, Somerfield MR, Pfister DG.

J Clin Oncol. 1999 Jun;17(6):1939-55. Review.

PMID:
10561236
8.

Clinical application of breast cancer risk assessment models.

Ready K, Litton JK, Arun BK.

Future Oncol. 2010 Mar;6(3):355-65. doi: 10.2217/fon.10.5. Review.

PMID:
20222793
9.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

10.

Prophylactic mastectomy for the prevention of breast cancer.

Lostumbo L, Carbine N, Wallace J, Ezzo J.

Cochrane Database Syst Rev. 2004 Oct 18;(4):CD002748. Review. Update in: Cochrane Database Syst Rev. 2010;(11):CD002748.

PMID:
15495033
11.

American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition.

Chlebowski RT, Col N, Winer EP, Collyar DE, Cummings SR, Vogel VG 3rd, Burstein HJ, Eisen A, Lipkus I, Pfister DG; American Society of Clinical Oncology Breast Cancer Technology Assessment Working Group.

J Clin Oncol. 2002 Aug 1;20(15):3328-43. Review.

PMID:
12149307
12.

Identifying and counseling women at increased risk for breast cancer.

Rhodes DJ.

Mayo Clin Proc. 2002 Apr;77(4):355-60; quiz 360-1. Review.

PMID:
11936931
13.

Tamoxifen for prevention of breast cancer.

Cersosimo RJ.

Ann Pharmacother. 2003 Feb;37(2):268-73. Review.

PMID:
12549959
14.

Reducing the risk of breast cancer with tamoxifen in women at increased risk.

Vogel VG.

J Clin Oncol. 2001 Sep 15;19(18 Suppl):87S-92S. Review.

PMID:
11560980
15.

Follow-up of the breast cancer prevention trial and the future of breast cancer prevention efforts.

Vogel VG.

Clin Cancer Res. 2001 Dec;7(12 Suppl):4413s-4418s; discussion 4411s-4412s. Review.

PMID:
11916233
16.

Opportunities and strategies for breast cancer prevention through risk reduction.

Mahoney MC, Bevers T, Linos E, Willett WC.

CA Cancer J Clin. 2008 Nov-Dec;58(6):347-71. doi: 10.3322/CA.2008.0016. Epub 2008 Nov 3. Review.

17.

A systematic review of breast cancer incidence risk prediction models with meta-analysis of their performance.

Meads C, Ahmed I, Riley RD.

Breast Cancer Res Treat. 2012 Apr;132(2):365-77. doi: 10.1007/s10549-011-1818-2. Epub 2011 Oct 22. Review.

PMID:
22037780
18.

Breast cancer prevention: a review of current evidence.

Vogel VG.

CA Cancer J Clin. 2000 May-Jun;50(3):156-70. Review.

19.

Breast cancer risk assessment models: applicability to African-American women.

Bondy ML, Newman LA.

Cancer. 2003 Jan 1;97(1 Suppl):230-5. Review.

20.

Tamoxifen for the primary prevention of breast cancer: a review and critique of the concept and trial.

Bush TL, Helzlsouer KJ.

Epidemiol Rev. 1993;15(1):233-43. Review.

PMID:
8405207

Supplemental Content

Support Center